Connecticut’s Cannabis Law Update: What Businesses Need to Know

The following article first appeared in the News & Insights section of Carmody Torrance Sandak Hennessey’s website. It is reposted here with permission.

---

Connecticut’s 2026 legislative session produced the most significant changes to the state’s cannabis laws since legalization.

Through HB 5350 and HB 5222, the General Assembly expanded opportunities for cannabis, hemp, and infused beverage businesses while also imposing sweeping new restrictions on social equity ownership, operational control, and business relationships.

The legislation affects nearly every segment of Connecticut’s regulated cannabis industry, from social equity cannabis license holders to infused beverage manufacturers, hemp businesses, to investors, and backers.

While the new laws create opportunities for businesses in the cannabis and infused beverage industries, they also introduce complex compliance requirements that may require businesses to revisit ownership structures, financing arrangements, operating agreements, and product classifications.

Businesses operating in Connecticut’s cannabis, hemp, food and beverage, and retail sectors should review these changes carefully before the new requirements take effect:

Key Business Impacts

From Nov. 1, 2026, HB 5222 significantly increases oversight of equity joint ventures by restricting agreements that transfer operational control away from social equity owners, creating new ownership review procedures, and expanding Social Equity Council enforcement authority.

In particular, there are: (a) new restrictions on ownership, operational control, and management/operational agreements involving social equity businesses, and (b) new annual certification requirements regarding social equity businesses’ ownership, control, and financings.

Notably, HB 5222 now imposes more significant regulatory and civil penalties for non-compliance, with possible enforcement actions resulting in fines of up to $10 million or actions against licenses.

New Compliance Requirements

Effective Oct. 1, 2026, licensed cannabis businesses should pay particular attention to several new compliance obligations, including:

• New limitations on financing and trade credit arrangements between cannabis establishments
• Updated packaging and labeling requirements, including expanded warning label requirements for certain high-potency products
• Simplified transportation and delivery rules under specified security conditions

Growth of the Infused Beverage Market

Effective Oct. 1, 2026, the legislation increases allowable THC limits for infused beverages, expands retail and on-premises sales opportunities for manufacturers, and creates additional pathways for hemp-derived ingredients to be used in regulated products.

Updated Hemp and Cannabis Definitions

The law clarifies how hemp-derived products, manufactured cannabinoids, and minor cannabinoids are regulated.

From Dec. 1, 2026, businesses should not assume that hemp-derived products fall outside Connecticut’s cannabis laws, as several products are now expressly regulated.

Expanded Medical Cannabis Definitions Access

Effective Oct. 1, 2026, Connecticut’s medical cannabis program will now serve qualifying out-of-state patients and caregivers, creating new opportunities for licensed dispensaries and hybrid retailers.

New Tax Structure

Adult-use cannabis will transition from a potency-based excise tax to a flat 10.75% retail cannabis tax from Oct. 1, simplifying pricing and tax administration for retailers.

Looking Ahead

Many of the legislation’s most significant provisions do not become effective until later in 2026.

Additional guidance from the Department of Consumer Protection and the Social Equity Council is expected and will likely shape how these changes are implemented in practice.

Because many of these changes affect ownership structures, financing arrangements, and management agreements, cannabis businesses should understand the new requirements before entering into future transactions.

---

About the authors: Ben Pomerantz is a partner with Carmody and a leading member of the firm’s cannabis industry group. Kevin Palumberi is a Carmody partner.